CUREVAC NV (CVAC) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CVAC • NL0015436031

4.66 USD
-0.01 (-0.21%)
At close: Jan 5, 2026
4.62 USD
-0.04 (-0.86%)
After Hours: 1/5/2026, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CVAC scores 3 out of 10 in our fundamental rating. CVAC was compared to 524 industry peers in the Biotechnology industry. CVAC has only an average score on both its financial health and profitability. CVAC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year CVAC has reported negative net income.
  • CVAC had a negative operating cash flow in the past year.
  • In the past 5 years CVAC reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
CVAC Yearly Net Income VS EBIT VS OCF VS FCFCVAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M -800M

1.2 Ratios

  • With an excellent Return On Assets value of 11.31%, CVAC belongs to the best of the industry, outperforming 93.77% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 14.79%, CVAC belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 14.12%, CVAC belongs to the best of the industry, outperforming 95.47% of the companies in the same industry.
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROIC 14.12%
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
CVAC Yearly ROA, ROE, ROICCVAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • Looking at the Profit Margin, with a value of 182.11%, CVAC belongs to the top of the industry, outperforming 98.49% of the companies in the same industry.
  • With an excellent Operating Margin value of 212.01%, CVAC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • CVAC has a better Gross Margin (93.01%) than 93.40% of its industry peers.
Industry RankSector Rank
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVAC Yearly Profit, Operating, Gross MarginsCVAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

  • CVAC has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for CVAC remains at a similar level compared to 1 year ago.
  • CVAC has more shares outstanding than it did 5 years ago.
  • CVAC has a better debt/assets ratio than last year.
CVAC Yearly Shares OutstandingCVAC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CVAC Yearly Total Debt VS Total AssetsCVAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.23 indicates that CVAC is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.23, CVAC is in the better half of the industry, outperforming 71.70% of the companies in the same industry.
  • CVAC has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • CVAC has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: CVAC outperforms 42.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC1.96
WACC7.21%
CVAC Yearly LT Debt VS Equity VS FCFCVAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • CVAC has a Current Ratio of 3.70. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
  • CVAC has a Current ratio of 3.70. This is comparable to the rest of the industry: CVAC outperforms 44.91% of its industry peers.
  • A Quick Ratio of 3.69 indicates that CVAC has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.69, CVAC perfoms like the industry average, outperforming 47.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.69
CVAC Yearly Current Assets VS Current LiabilitesCVAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

2

3. Growth

3.1 Past

  • The earnings per share for CVAC have decreased strongly by -247.92% in the last year.
  • The Revenue for CVAC has decreased by -86.98% in the past year. This is quite bad
  • CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%

3.2 Future

  • CVAC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
  • The Revenue is expected to decrease by -11.14% on average over the next years. This is quite bad
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CVAC Yearly Revenue VS EstimatesCVAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CVAC Yearly EPS VS EstimatesCVAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CVAC. In the last year negative earnings were reported.
  • Also next year CVAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVAC Price Earnings VS Forward Price EarningsCVAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.08
CVAC Per share dataCVAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • CVAC's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%

More info and screens

0

5. Dividend

5.1 Amount

  • CVAC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CUREVAC NV

NASDAQ:CVAC (1/5/2026, 8:00:00 PM)

After market: 4.62 -0.04 (-0.86%)

4.66

-0.01 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)04-08
Inst Owners10.45%
Inst Owner Change-4.34%
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap1.05B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target5.57 (19.53%)
Short Float %0.41%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)16.57%
PT rev (3m)13.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)20.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.77
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.07
EV/EBITDA 3.08
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.36
BVpS4.49
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROCE 16.62%
ROIC 14.12%
ROICexc 26.37%
ROICexgc 27.79%
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
FCFM N/A
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.18
Cap/Depr 28.09%
Cap/Sales 7.01%
Interest Coverage 66.45
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.69
Altman-Z 4.23
F-Score3
WACC7.21%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A

CUREVAC NV / CVAC FAQ

Can you provide the ChartMill fundamental rating for CUREVAC NV?

ChartMill assigns a fundamental rating of 4 / 10 to CVAC.


Can you provide the valuation status for CUREVAC NV?

ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.


How profitable is CUREVAC NV (CVAC) stock?

CUREVAC NV (CVAC) has a profitability rating of 5 / 10.


What is the financial health of CUREVAC NV (CVAC) stock?

The financial health rating of CUREVAC NV (CVAC) is 5 / 10.


What is the expected EPS growth for CUREVAC NV (CVAC) stock?

The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -163.99% in the next year.